The US Food and Drug Administration (FDA) has approved intramuscular (IM) administration of peginterferon β-1a (Plegridy, Biogen) for patients with relapsing forms of multiple sclerosis (MS). "The new ...
This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, ...
The European Commission (EC) has approved a new intramuscular (IM) injection route of administration for Biogen’s Plegridy for the treatment of relapsing-remitting multiple sclerosis (RRMS). Plegridy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback